Emerald Mutual Fund Advisers Trust Acquires New Holdings in CeriBell (NASDAQ:CBLL)

Emerald Mutual Fund Advisers Trust purchased a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 77,835 shares of the company's stock, valued at approximately $2,014,000. Emerald Mutual Fund Advisers Trust owned about 0.22% of CeriBell at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc acquired a new stake in CeriBell during the 4th quarter valued at approximately $32,000. Summit Investment Advisors Inc. acquired a new stake in shares of CeriBell during the fourth quarter worth $33,000. Tower Research Capital LLC TRC bought a new position in CeriBell during the fourth quarter worth $37,000. PNC Financial Services Group Inc. acquired a new position in CeriBell in the fourth quarter valued at $47,000. Finally, Corebridge Financial Inc. bought a new stake in CeriBell during the fourth quarter valued at $158,000.

CeriBell Stock Up 0.2 %

Shares of CBLL traded up $0.04 during trading hours on Friday, reaching $16.32. The stock had a trading volume of 208,040 shares, compared to its average volume of 270,817. The stock's 50-day moving average is $18.85. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. On average, analysts expect that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling at CeriBell

In related news, CEO Xingjuan Chao sold 15,628 shares of the stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the transaction, the chief executive officer now owns 727,151 shares in the company, valued at approximately $10,987,251.61. This represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 24,700 shares of company stock worth $372,434.

Wall Street Analyst Weigh In

Several research firms recently commented on CBLL. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell has an average rating of "Buy" and an average price target of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.